# Fiona C. Thistlethwaite, MB BChir – FDA 483, May 1, 2026

Source: https://www.keypedia.com/records/483/fiona-c-thistlethwaite-mb-bchir/059daa3b-302d-464f-b337-0ad2cbe9d08c

> FDA 483 for Fiona C. Thistlethwaite, MB BChir on May 01, 2026. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Fiona C. Thistlethwaite, MB BChir
- Inspection Date: 2026-05-01
- Product Type: biologics
- Office Name: Office of Inspections and Investigations
- Summary: An FDA inspection of Fiona C. Thistlethwaite, MB BChir, a clinical investigator in Manchester, United Kingdom, revealed significant deviations from good clinical practices during a Phase 2 clinical trial. The investigator failed to conduct a protocol-required procedure prior to dosing a subject and did not report a subject's condition as an adverse event. These findings indicate serious non-compliance with the investigational plan.

## Related Officers

- [investigator](https://www.keypedia.com/people/sherri-n-rohlf/41090ab1-83d1-4e95-92ea-0cfca5cecdb6)

Company: https://www.keypedia.com/companies/fiona-c-thistlethwaite-mb-bchir/abd8aa1f-292e-48ec-a585-dc5334409c4f

Office: https://www.keypedia.com/offices/office-of-inspections-and-investigations/7dd0b904-a3df-46bc-a7b2-70ddb6f809c8